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Background: We previously reported that Waon therapy upregulates endothelial nitric oxide
synthase protein, and augments ischemia-induced angiogenesis in mice with hindlimb ischemia,
and it improves limb ischemia in patients with peripheral arterial disease (PAD). The aim of
this study was to investigate the underlying mechanism of Waon therapy for the treatment
of patients with PAD, and to determine whether Waon therapy can mobilize blood-derived
progenitor cells.
Methods: 21 consecutive PAD patients received standard medications, and were randomly
divided into control (n = 10) and Waon therapy groups (n = 11). The Waon therapy group received
Waon therapy daily for 6 weeks. The control group continued conventional therapy for 6 weeks.
Leg pain was scored using a visual analogue scale. The ankle-brachial pressure index (ABPI) and
the 6-min walking distance were measured at baseline and 6 weeks after therapy. Frequency of
circulating CD34+ progenitor cell numbers was measured by quantitative real-time polymerase
chain reaction, and the serum nitrate and nitrite levels were also measured at baseline and 6
weeks after therapy.
Results: The leg pain score, ABPI and the 6-min walking distance improved signiﬁcantly after
6 weeks in the Waon therapy group, but not in the control group. Frequency of circulating
CD34+ cells increased after 6 weeks of Waon therapy [2.0± 1.2 (×10−4) at baseline to 3.9± 1.9
(×10−4), p = 0.015], while it remained unchanged in the control group [1.8± 1.8 (×10−4) at
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baseline to 1.2± 0.9 (×10−4)]. Serum nitrate and nitrite levels increased signiﬁcantly after Waon
therapy (29.6± 17.6 to 36.0± 17.7mol/ml, p < 0.05), but not in the control group (34.4± 9.4
to 38.3± 8.8mol/ml).



























































































after the last treatment in the Waon therapy group.ischemia in patients with PAD
© 2010 Japanese College of C
ntroduction
eripheral arterial disease (PAD) is associated with
ecreased functional capacity and quality of life. Fur-
hermore, patients with PAD have a higher rate of limb
mputation and an increased risk of death compared with
he general population. Patients with chronic critical limb
schemia have a 20% mortality rate per year with many
atients being poor candidates for revascularization pro-
edures [1]. Therapeutic angiogenesis and vasculogenesis
ay provide a treatment option for those patients with
ritical limb ischemia who are not suited for conventional
evascularization therapy [2]. Some attempts at therapeu-
ic angiogenesis have induced gene transfer using naked
lasmid DNA encoding vascular endothelial growth factor
VEGF), which has demonstrated some promise in improv-
ng symptoms of critical limb ischemia [3], although not all
tudies have shown a beneﬁt [4,5]. In addition, research
as examined endothelial progenitor cells, which originate
rom bone marrow and circulate in the peripheral blood,
nd are known to participate in postnatal neovasculariza-
ion [6,7]. There is evidence that autologous implantation
f bone marrow mononuclear cells could be effective for
chieving therapeutic angiogenesis [8,9]. These therapeutic
ngiogenesis trials have shown promising early efﬁcacy, but
urther trials are warranted.
We have developed a form of thermal therapy, termed
aon therapy, which uses a dry sauna maintained at a tem-
erature of 60 ◦C and differs from a traditional sauna. We
reviously reported that repeated Waon therapy improves
emodynamics and ameliorates symptoms and ventricu-
ar arrhythmias in patients with chronic heart failure
CHF) [10—12]. Furthermore, we reported that repeated
aon therapy improves vascular endothelial dysfunction in
atients with CHF, and in patients with coronary risk factors
uch as hypertension, hyperlipidemia, diabetes mellitus,
nd smoking [13,14]. We also demonstrated that the molec-
lar mechanism by which repeated Waon therapy improves
ascular ﬂow and endothelial function is through increased
ndothelial nitric oxide synthase (eNOS) expression [15,16].
Nitric oxide (NO) is constitutively produced by eNOS,
nd is a mediator of angiogenesis. Waon therapy increases
NOS protein expression, blood ﬂow, and capillary density
n a mouse model of hindlimb ischemia [17]. Furthermore,
aon therapy does not increase blood ﬂow and capillary
ensity in eNOS-deﬁcient mice, which demonstrates that
NOS is a critical regulator of angiogenesis during Waon ther-
py. Recently, we reported that Waon therapy is safe and
mproves leg pain, status, and blood ﬂow in patients with
AD [18,19].
This study was performed to conﬁrm the beneﬁcial
ffects of Waon therapy using the infrared-ray dry sauna,




‘on therapy is a highly promising therapy for patients with PAD.
ology. Published by Elsevier Ireland Ltd. All rights reserved.
herapy may be beneﬁcial in the treatment patients with
AD. In particular, we wanted to determine whether Waon




he present study included patients with PAD with inter-
ittent claudication for a minimum of 4 weeks without
vidence of improvement despite conventional therapies.
nclusion criteria were (1) a resting ankle-brachial pressure
ndex (ABPI) <0.75 in the affected limb on 2 consecu-
ive examinations performed at least 1 week apart, (2)
ower limb artery lesions were detected with computed
omographic angiography (CTA), magnetic resonance angiog-
aphy (MRA) or color duplex ultrasound. 21 consecutive PAD
atients were enrolled, and were randomly divided into con-
rol (n = 10) and Waon therapy groups (n = 11). They were
llowed to continue taking antiplatelet drugs, provided that
hese therapies had been used for a minimum of 6 months
efore the enrollment. In the Waon therapy group, they
ad Waon therapy daily for 6 weeks. In the control group,
hey had only conventional PAD therapy for 6 weeks. All
atients gave their written informed consent. This study
esign was unanimously approved by the Ethics Committee
f Kagoshima University.
aon therapy
aon therapy, a form of thermal therapy that uses a far
nfrared-ray dry sauna at 60 ◦C and differs from the tra-
itional sauna in that it has no hydration pressure, was
erformed as previously reported [18]. The patients were
laced in a 60 ◦C dry sauna system for 15min; after leav-
ng the sauna, they underwent bed rest with a blanket to
eep them warm for an additional 30min. All patients were
eighed before and after the therapy, and oral hydration
ith water was used to compensate for weight lost due to
erspiration.
Waon therapy was performed once a day, 5 days a week,
or a total of 6 weeks in the Waon therapy group. To rule out
n acute effect of Waon therapy, all measurements were
erformed before the ﬁrst treatment and on the next dayeasurements
eg pain was scored using a visual analogue scale, with
marked 10-cm line extending from ‘‘no pain: 0’’ to




























cWaon therapy mobilizes CD34+ cells
quotient of the absolute ankle pressure to the right brachial
pressure using an oscillometric method by Form/ABPI (Colin,
Komaki, Japan) as reported previously [20]. Six-minute
(6-min) walking distance was measured to evaluate exer-
cise capacity. The serum nitrate (NO3), nitrite (NO2), and
VEGF levels were measured. The pain score, ABPI, and 6-
min walking distance were measured at baseline and after
6 weeks.
Analysis of CD34 mRNA for detection of circulating
CD34+ cells in the periphery
To detect the shift of circulating CD34+ progenitor cells
in the periphery with higher sensitivity, quantitative real-
time polymerase chain reaction (PCR) for CD34 messenger
RNA (mRNA) was performed with the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene as an internal
control. Patients’ peripheral blood mononuclear cells were
harvested at baseline and after 6 weeks. Peripheral blood
mononuclear cells (PBMC) (approximately 106/tube) were
stored at −80 ◦C and later used for RNA extraction, cDNA
synthesis, and quantitative real-time PCR.
Total RNA was extracted from patients’ PBMC using the
guanidine isothiocyanate method (RNeasy Mini Kit, Qiagen,
Hilden, Germany), and was then transcribed to cDNA (Tran-
scriptor First Strand cDNA Synthesis Kit, Roche Diagnostics,
Basel, Switzerland) according to the manufacturer’s instruc-
tions. Real-time quantitative PCR analysis was performed
using a LightCycler system and LC FastStart DNA Master
Hybridization Probes (Roche Diagnostics), and 1l of cDNA
in a ﬁnal reaction volume of 20l. Primers for human CD34
(GenBank accession no. M81104) were designed as follows:
(forward) 5′-CTCAGTGTCTACTGCTGGTCT-3′ and (reverse) 5′-
GGAATAGCTCTGGTGGCTT-3′. The taqman probe sequence
was 5′-FAM-CAACTTATGAAAAAGCACCAATCTGACCTG-TAMRA-
3′. Thermal cycler parameters included 10min at 95 ◦C, 40
cycles of 95 ◦C for 10 s, and 62 ◦C for 20 s. The size of the
amplicon of the CD34 gene was 143 bp. The expression level
of the GAPDH (GenBank accession no. M33197) gene was
measured as an internal reference with a standard curve for






Table 1 Characteristics of patients.
Control (n = 10)
Gender (male/female) 10/0
Age (years) 75± 5
BMI 24.0± 1.3
ABPI 0.50± 0.21
Hyperlipidemia, n (%) 5 (50%)
Diabetes mellitus, n (%) 6 (60%)
Hypertension, n (%) 9 (90%)
Smoking, n (%) 8 (80%)
Medications
Antiplatelets, n (%) 10 (100%)
ACEI or ARB, n (%) 4 (40%)
Statin, n (%) 5 (50%)
PGI2 analogue, n (%) 3 (33%)363
ll primers were purchased from Nihon Gene Research Labo-
atories (Sendai, Japan). The frequency of CD34+ cells in the
eriphery was determined as the ratio of the mRNA level of
hese genes as follows: absolute copy number of CD34 gene
n 1l of cDNA/absolute copy number of GAPDH gene in 1l
f cDNA.
tatistical analysis
ll data are expressed as mean values± SD. Data at baseline
nd after 6 weeks were compared using the paired t-test.
ifferences in patients’ characteristics were evaluated using
he chi-squared test and the unpaired t-test. A value of
< 0.05 was considered statistically signiﬁcant.
esults
linical characteristics
he patients’ clinical characteristics are summarized in
able 1. There were no signiﬁcant differences in age,
ody mass index, ABPI, hyperlipidemia, diabetes mellitus,
ypertension, and smoking between the control and the
aon therapy groups. In addition, there were no signiﬁ-
ant differences in the use of medications for PAD, such
s antiplatelets, angiotensin-converting enzyme inhibitors,
ngiotensin receptor blockers, or statins between the two
roups. There was a signiﬁcant difference in gender between
he two groups.
All patients enrolled in the trial completed the study
ithout any adverse events. During the trial, no patients
eveloped signiﬁcant laboratory test abnormalities, includ-
ng those for blood cell counts, electrolyte concentrations,
hemistry and lipid proﬁles, tumor markers, and inﬂam-
atory markers. No changes in diabetic retinopathy were
bserved on fundoscopic examination, and no latent neo-
lasms developed. Transient leg pain during Waon therapy
as seen, but it disappeared after a few sessions of Waon
herapy.
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Figure 1 Changes in leg pain, walking distance, and ankle-











































38.3± 8.8mol/ml, Fig. 3).
There were no signiﬁcant differences in VEGF levels at
baseline and after 6 weeks in both groups (control group:
39.2± 21.7 to 42.5± 21.6 pg/ml; Waon therapy group:
70.2± 46.3 to 40.2± 40.5 pg/ml, Fig. 4). VEGF level at base-visual analogue scale (10: severe pain; 0: no pain). (B) 6-min
alking distance. (C) ABPI open bars: at baseline; solid bars:
fter 6 weeks.
hanges in leg pain, walking distance, and ABPI
herapeutic beneﬁt was demonstrated by regression of
eg pain in all patients treated with Waon therapy. The
ain score evaluated using a visual analogue scale was sig-
iﬁcantly decreased in the Waon therapy group after 6
eeks (8.1± 0.7 to 2.8± 1.1, p < 0.05), while it remained
nchanged in the control group (8.4± 0.8 to 8.2± 1.1,
ig. 1A).
Exercise performance improved signiﬁcantly in the Waon
herapy group (Fig. 1B). After 6 weeks of Waon therapy, the
-min walking distance increased from 149± 104m at base-
ine to 230± 154m at 6 weeks after Waon therapy (p < 0.01),
hile it did not change in the control group (136± 76 to
32± 72m, Fig. 1B).The mean ABPI increased signiﬁcantly from 0.55± 0.20 at
aseline to 0.60± 0.22 after 6 weeks in the Waon therapy
roup (p < 0.01, Fig. 1C), but it did not change in the control
roup (0.50± 0.21 to 0.49± 0.20).
F
bigure 2 Changes in frequency of mobilized circulatory CD34+
ells. Open bars: at baseline; solid bars: after 6 weeks. GAPDH,
lyceraldehyde-3-phosphate dehydrogenase.
etection of circulating CD34+ cells by
uantitative real-time PCR
requency of circulating CD34 positive cell numbers was
easured at baseline and after 6 weeks by quantitative
eal-time PCR using the mRNA CD34/GAPDH ratio (Fig. 2).
n the PAD group, the mRNA CD34/GAPDH ratio increased
.0-fold, from 2.0± 1.2 (×10−4) at baseline to 3.9± 1.9
×10−4) after 6 weeks of Waon therapy (p = 0.015), while the
RNA CD34/GAPDH ratio in the control group was 1.8± 1.8
×10−4) at baseline and 1.2± 0.9 (×10−4) after 6 weeks (no
igniﬁcant difference). Repeated Waon therapy appears to
obilize progenitor cells among PAD patients, and this might
e helpful for the repair or regeneration of damaged vessels.
O production and VEGF levels
erum nitrate (NO3), nitrite (NO2), and VEGF lev-
ls were measured in both groups. In the Waon
herapy group, the serum nitrate and nitrite levels
ncreased signiﬁcantly after 6 weeks of Waon therapy
29.6± 17.6 to 36.0± 17.7mol/ml, p < 0.05), while it
emained unchanged in the control group (34.4± 9.4 toigure 3 Changes in serum nitrate and nitrite levels. Open
ars: at baseline; solid bars: after 6 weeks.














































The authors gratefully acknowledge Mrs. Eriko Masuyama,Figure 4 Changes in serum vascular endothelial growth factor
(VEGF) levels. Open bars: at base line; solid bars: after 6 weeks.
line of Waon therapy group was signiﬁcantly higher than that
of control group (p = 0.041).
Discussion
We have developed thermal therapy using a 60 ◦C dry sauna
and showed that it improves hemodynamic parameters,
endothelial function, clinical symptoms, and prognosis in
many CHF patients [10—12,21—23]. Generally, thermal ther-
apy at very high temperature was originally used to treat
localized cancer. However, the therapy we developed to
treat cardiovascular diseases is quite different in that it con-
sists of systemic soothing warmth that comfortably refreshes
the mind and body. Therefore, we have changed the name
from thermal to Waon therapy, since ‘‘Waon’’ in Japanese
means soothing warmth [24].
In the present study, it was conﬁrmed that Waon therapy
is safe and potentially effective for patients with severe PAD,
as evidenced by substantial decreases in the pain score and
increases in ABPI and walking distance.
The goal in this study was to examine the underlying
mechanism of Waon therapy for the treatment of PAD, and
to see whether Waon therapy could mobilize blood-derived
progenitor cells for local vascular regeneration. Recently,
ﬂow cytometry has been used to detect CD34+ progenitor
cells in the periphery; however, the frequency of CD34+
cells in the periphery under normal, steady state condi-
tions is less than 0.01%, which is just at the limit of the
detectable range of ﬂow cytometers. It is widely known that
granulocyte-colony stimulating factor (G-CSF) can mobilize
a large number of CD34+ hematopoietic progenitor cells
from the bone marrow, which can be easily detected by
ﬂow cytometry. Nonetheless, we speculated that progenitor
mobilization by our Waon therapy might be much weaker
than that with G-CSF administration. To detect the change
in circulating CD34+ cells with higher sensitivity, we devel-
oped a quantitative real-time PCR for CD34 mRNA using the
GAPDH gene as an internal control, and found that circulat-
ing CD34+ cells were mobilized by repeated Waon therapy
in patients with PAD.
We previously reported that angiogenesis was induced via
eNOS using Waon therapy in mice with hindlimb ischemia
[17]. NO is a mediator of angiogenesis and plays a key role





herapy increases cardiac output, shear stress of the vessel
all, and, ultimately, eNOS expression.
PAD patients are characterized by reduced systemic NO
ioactivity. The impaired neovascularization in mice lacking
NOS is related to a defect in progenitor cell mobilization.
NOS expressed by bone marrow stromal cells inﬂuences
ecruitment of stem and progenitor cells [25]. In the present
tudy, Waon therapy increased NO and circulating endothe-
ial progenitor cells (EPC), which suggests that this therapy
ay mobilize EPC through an eNOS-dependent mechanism.
Some strategies to regulate the mobilization of progeni-
or cells through the eNOS pathway have been reported [25].
tatin therapy has improved EPC mobilization, myocardial
eovascularization, left ventricular function, and survival
fter experimental myocardial infarction [26]. Estrogen
herapy has augmented EPC incorporation into sites of
yocardial neovascularization after myocardial infarction
27] and physical training also has increased EPCs and
nhanced angiogenesis [28].
NO is an angiogenic mediator acting downstream of
EGF; impaired angiogenesis in eNOS-deﬁcient mice was not
mproved by administration of VEGF [29], and transgenic
ice overexpressing eNOS did not show a greater increase
n VEGF expression in hindlimb ischemia [30]. Although
aon therapy did not increase expression of VEGF in the
schemic hindlimb, this therapy augmented angiogenesis
y increasing eNOS expression in the course of ischemia-
nduced VEGF expression [17]. Therefore, we think CD34+
ells were recruited in PAD patients who had the ischemia-
nduced VEGF. Furthermore, in this study, the concentration
f VEGF which was upregulated by ischemia decreased in
he course of improvement of limb ischemia after Waon
herapy.
tudy limitations
here are several limitations in this study. VEGF levels at
aseline of the two groups were different. This difference
ay have an inﬂuence on results, although Waon therapy did
ot increase the VEGF levels. Further large study is required
o resolve this grouping problem.
There was no signiﬁcant correlation between CD34+ cells,
O, and VEGF in the present study. There may be a time lag
or a rise of these factors. Further study that measures these
actors in several points will clarify the correlation of these
actors.
onclusions
aon therapy mobilized circulating endothelial progenitor
ells and improved limb ischemia in PAD patients. Waon
herapy is a highly promising therapy for PAD patients.
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